Loading...

Home
ETF
NBIX

NBIX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

NBIX News

Neurocrine Presents INGREZZA Data and Completes Soleno Acquisition

May 19 2026NASDAQ.COM

Neurocrine Presents New Data on INGREZZA for Mild Tardive Dyskinesia

May 18 2026PRnewswire

INGREZZA Shows Significant Efficacy in Mild Tardive Dyskinesia Treatment

May 18 2026Newsfilter

Neurocrine Completes Acquisition of Soleno, Strengthening Leadership in Endocrinology

May 18 2026PRnewswire

FDA Grants Orphan Drug Designation to Neurocrine's NBIB-223

May 07 2026seekingalpha

First Expert Recommendations for Glucocorticoid Dose Reduction Published

May 06 2026PRnewswire

New Algorithms Aid in Reducing Hormone Doses for CAH Patients

May 06 2026Newsfilter

Neurocrine Biosciences Reports Record Q1 2026 Earnings Driven by INGREZZA

May 06 2026seekingalpha

Neurocrine Biosciences Q1 Earnings Exceed Expectations

May 05 2026seekingalpha

Investigation Alerts for Multiple Company Mergers

May 05 2026Globenewswire

Neurocrine Biosciences Q1 Earnings Announcement Scheduled

May 04 2026seekingalpha

Neurocrine Biosciences Releases Survey Findings on Tardive Dyskinesia Impact

May 04 2026PRnewswire

Survey Reveals Tardive Dyskinesia's Impact on Employment

May 04 2026Newsfilter

Neurocrine Initiates Phase 1 Study for Obesity Treatment

May 04 2026PRnewswire

Neurocrine Initiates Phase 1 Study for NBIP-'2118 Weight Loss Therapy

May 04 2026Newsfilter

Neurocrine Presents New Two-Year Data on CAH Treatment

May 01 2026PRnewswire